First-Line Carboplatin Plus Pemetrexed with Pemetrexed Maintenance in HIV+ Patients with Advanced Non-Squamous Non-Small Cell Lung Cancer: The Phase II IFCT-1001 CHIVA Trial.

Date publication

mai 2020

Journal

The European respiratory journal

Auteurs

Membres identifiés du Cancéropôle Est :
Dr FRAISSE Philippe

Tous les auteurs :
Lavole A, Greillier L, Mazières J, Monnet I, Kiakouama-Maleka L, Quantin X, Spano JP, Herve L, Fraisse P, Janicot H, Audigier-Valette C, Langlais A, Morin F, Makinson A, Cadranel J,

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/32444410

Résumé

HIV infection is an exclusion criterion in lung cancer trials. This multicenter phase II trial aimed to assess feasibility, efficacy and safety of first-line carboplatin plus pemetrexed (CaP) followed by pemetrexed (P) maintenance in people living with HIV (PLHIV) with advanced non-squamous non-small cell lung cancer (NS-NSCLC).

Référence

Eur. Respir. J.. 2020 May 22;: